
News|Podcasts|April 29, 2025
Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations
Author(s)Alexandra Gerlach, Associate Editor
Pharmacists discuss how drug design impacts drug efficacy and indications for HER2-low and -ultra-low breast cancer.
Advertisement
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Updates in Treatment of Unresectable Hepatocellular Carcinoma
2
FDA Approves Rucaparib for the Treatment of Adults With mCRPC
3
Infliximab and Adalimumab Biosimilars Maintain Comparable Safety, Efficacy, Immunogenicity in IBD
4
Notable Updates in Medication Therapy Management in 2025
5











































































































































































































